These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35703216)

  • 1. Clinical utility of bone turnover markers in patients with chronic kidney disease.
    Smout D; Jørgensen HS; Cavalier E; Evenepoel P
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):332-338. PubMed ID: 35703216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis.
    Brouwers P; Bouquegneau A; Cavalier E
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):149-156. PubMed ID: 38804196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults.
    Glendenning P; Chubb SAP; Vasikaran S
    Clin Chim Acta; 2018 Jun; 481():161-170. PubMed ID: 29544749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility of bone marker measurements in osteoporosis.
    Wheater G; Elshahaly M; Tuck SP; Datta HK; van Laar JM
    J Transl Med; 2013 Aug; 11():201. PubMed ID: 23984630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis.
    Camacho PM; Lopez NA
    Clin Chem Lab Med; 2008; 46(10):1345-57. PubMed ID: 18844486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.
    Greenblatt MB; Tsai JN; Wein MN
    Clin Chem; 2017 Feb; 63(2):464-474. PubMed ID: 27940448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
    Lorentzon M; Branco J; Brandi ML; Bruyère O; Chapurlat R; Cooper C; Cortet B; Diez-Perez A; Ferrari S; Gasparik A; Herrmann M; Jorgensen NR; Kanis J; Kaufman JM; Laslop A; Locquet M; Matijevic R; McCloskey E; Minisola S; Pikner R; Reginster JY; Rizzoli R; Szulc P; Vlaskovska M; Cavalier E
    Adv Ther; 2019 Oct; 36(10):2811-2824. PubMed ID: 31440982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis.
    Biver E; Chopin F; Coiffier G; Brentano TF; Bouvard B; Garnero P; Cortet B
    Joint Bone Spine; 2012 Jan; 79(1):20-5. PubMed ID: 21724445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of bone turnover markers in clinical practice.
    Biver E
    Curr Opin Endocrinol Diabetes Obes; 2012 Dec; 19(6):468-73. PubMed ID: 23128576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
    Hsu CY; Chen LR; Chen KH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder.
    Costa AG; Bilezikian JP; Lewiecki EM
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):324-9. PubMed ID: 26050118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone turnover marker].
    Miura M; Satoh Y
    Nihon Rinsho; 2015 Oct; 73(10):1649-58. PubMed ID: 26529926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review.
    Ginsberg C; Ix JH
    Am J Kidney Dis; 2022 Mar; 79(3):427-436. PubMed ID: 34419519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of biochemical markers in the management of osteoporosis.
    Henriksen K; Christiansen C; Karsdal MA
    Climacteric; 2015; 18 Suppl 2():10-8. PubMed ID: 26507704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
    Vasikaran S; Eastell R; Bruyère O; Foldes AJ; Garnero P; Griesmacher A; McClung M; Morris HA; Silverman S; Trenti T; Wahl DA; Cooper C; Kanis JA;
    Osteoporos Int; 2011 Feb; 22(2):391-420. PubMed ID: 21184054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment.
    Haarhaus M; Evenepoel P; ;
    Kidney Int; 2021 Sep; 100(3):546-558. PubMed ID: 34102219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis.
    Vasikaran SD; Miura M; Pikner R; Bhattoa HP; Cavalier E;
    Calcif Tissue Int; 2023 Feb; 112(2):148-157. PubMed ID: 34846540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.
    Amerling R; Harbord NB; Pullman J; Feinfeld DA
    Blood Purif; 2010; 29(3):293-9. PubMed ID: 20090316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical Markers of Bone Turnover and their Role in Osteoporosis Diagnosis: A Narrative Review.
    Khashayar P; Meybodi HA; Amoabediny G; Larijani B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):79-89. PubMed ID: 26246012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.